Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Over the last 12 months, insiders at Aclarion, Inc. have bought $0 and sold $0 worth of Aclarion, Inc. stock.
On average, over the past 5 years, insiders at Aclarion, Inc. have bought $34,309 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1 shares for transaction amount of $1,000 was made by Thramann Jeffrey John (Executive Chairman) on 2023‑02‑16.
2023-02-16 | Executive Chairman | 1 – | $1,000.00 | $1,000 | -26.29% | |||
2022-12-29 | Chief Financial Officer | 22,404.44 0.2978% | $0.45 | $10,000 | +10.57% | |||
2022-12-29 | Chief Executive Officer | 16,211 0.2623% | $0.54 | $8,807 | +10.57% | |||
2022-12-28 | Chief Executive Officer | 2,289 0.0375% | $0.42 | $961 | +44.79% | |||
2022-04-21 | 11,000 0.2249% | $4.35 | $47,850 | -68.80% |
Wesemann William | 52736 0.525% | $0.19 | 1 | 0 | <0.0001% | |
Lorbiecki John Paul | Chief Financial Officer | 22404 0.223% | $0.19 | 1 | 0 | +10.57% |
Ness Brent | Chief Executive Officer | 19500 0.1941% | $0.19 | 2 | 0 | +27.68% |
Thramann Jeffrey John | Executive Chairman | 1 0% | $0.19 | 1 | 0 | <0.0001% |